STEM PHARM, INCORPORATED
Madison, WI · Biotech · Private
Hydrogel-enabled neural organoids incorporating tumor-associated immune cells for glioblastoma modeling and drug screening
- Grants
- $8.3M
- 17 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Biomaterials for mRNA-based cellular reprogramming | $290,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Biomaterials for mRNA based cellular reprogramming | $290,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Synthetic biomaterials designed for the generation and maintenance of mouse neural organoids for in vitro toxicity screening | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Synthetic biomaterials designed for the generation of mouse neural organoids for in vitro toxicity screening. | $280,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Synthetic hydrogels for biomanufacturing of iPSC-derived neural cells for precision medicine | $224,976 | |
| Federal grant | Department of Health and Human Services · Phase I · Synthetic biomaterials designed for the generation of mouse neural organoids for in vitro toxicity screening. | $55,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Hydrogel-enabled self-assembled human brain organoids for developmental neurotoxicity applications | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Synthetic hydrogels for biomanufacturing of iPSC-derived neural cells for precision medicine | $868,100 | |
| Federal grant | Department of Health and Human Services · Phase II · Synthetic hydrogels for biomanufacturing of iPSC-derived neural cells for precision medicine | $1,546,685 | |
| Federal grant | Department of Health and Human Services · Phase II · Hydrogel-enabled self-assembled human brain organoids for neurotoxicity applications | $930,433 | |
| Federal grant | Department of Health and Human Services · Phase II · Synthetic hydrogels for biomanufacturing of iPSC-derived neural cells for precision medicine | $678,585 | |
| Federal grant | Department of Health and Human Services · Phase II · Hydrogel-enabled self-assembled human brain organoids for neurotoxicity applications | $783,533 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Neural organoid models of the immunological microenvironment of glioblastoma for drug discovery applications | $406,500 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Neural organoid models of the immunological microenvironment of glioblastoma for drug discovery applications | $406,500 | |
| Federal grant | Department of Health and Human Services · Phase I · Human Neural Organoid Modeling of Alzheimer's Disease Neuroinflammation for Drug Discovery | $499,903 | |
| Federal grant | Department of Health and Human Services · Phase I · Human Neural Organoid Modeling of Alzheimer's Disease Neuroinflammation for Drug Discovery | $55,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development and Validation of a CNS Organoid Model of Temporal Lobe Epilepsy for Drug Discovery | $499,953 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1561 | Sudo Biosciences | — | $63M |
| 1562 | TROPHOGEN INC | — | — |
| 1563 | Anjon Biologics Inc. | — | — |
| 1564 | STEM PHARM, INCORPORATED | — | — |
| 1565 | RELMADA THERAPEUTICS, INC. | — | $33M |
| 1566 | CELLOLOGI, LLC | — | — |
| 1567 | AUXAGEN, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Visible Light Polymerization Of Polyethylene Glycol (peg) Hydrogelsapplication
- Visible Light Polymerization Of Polyethylene Glycol (peg) Hydrogelsapplication
- Visible Light Polymerization Of Polyethylene Glycol (peg) Hydrogelsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.